GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The companyÂ’s lead product candidate is CGF166, which is in Phase I/II clinical trial for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to generate vaccine candidates for the prevention of malaria; Laboratory of Malaria Immunology and Vaccinology to create and test various malaria vaccine candidates; and Merial to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland.
